Hikma Pharmaceuticals (LON:HIK) Earns “Buy” Rating from Berenberg Bank

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reaffirmed by Berenberg Bank in a report issued on Monday,Digital Look reports. They presently have a GBX 2,560 ($33.14) price objective on the stock. Berenberg Bank’s target price would indicate a potential upside of 23.67% from the company’s previous close.

Separately, JPMorgan Chase & Co. restated an “overweight” rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th.

Hikma Pharmaceuticals Stock Down 1.6 %

Shares of LON HIK traded down GBX 34 ($0.44) during midday trading on Monday, reaching GBX 2,070 ($26.80). 341,885 shares of the company’s stock were exchanged, compared to its average volume of 2,103,955. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. Hikma Pharmaceuticals has a 52-week low of GBX 1,750 ($22.66) and a 52-week high of GBX 2,360 ($30.55). The business’s fifty day moving average price is GBX 2,175.22 and its two-hundred day moving average price is GBX 2,013.78. The stock has a market capitalization of £5.74 billion, a PE ratio of 20.31, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.